the number of TAAA cases performed nationally and a decline in the rate of ruptured TAAA (P < .001).
for noncontinuous variables and the unpaired ttest for continuous variables.
Results: Of 303 patients, 15 required correction for SS (eight of 232 AVF and seven of 71 AVG). Eight were ligated; two were initially banded, then ligated; and five underwent distal revascularization with interval ligation. Coronary artery disease was more prevalent in SS patients (66.7% vs 25%; P ¼ .001); the same was found with peripheral arterial disease (40% vs 13.8%; P ¼ .02). Further, more patients with SS were on Plavix for cardiovascular reasons (40% vs 9%; P ¼ .002). SS only developed with AVF/AVG using brachial artery inflow. No cases of SS arose from radial/ulnar inflow (P ¼ .03). All AVGs with SS had a straight configuration; no looped AVG developed steal (P ¼ .02). Other patient characteristics such as age, sex, race, hypertension, diabetes mellitus, congestive heart failure, cerebrovascular accident, cause of end-stage renal disease, and other medication history were not different between groups.
Conclusions: Clinically significant SS is associated with disease in coronary and peripheral arterial beds. In addition, the use of brachial artery inflow and straight AVG configuration are associated with SS. Patients with these characteristics need additional vigilance for steal-associated symptoms. Objectives: The current standard of surgical repair for type A aortic dissection (TAAD) does not guarantee freedom from subsequent aortic operations; therefore, consideration of simultaneous treatment beyond the ascending aorta is warranted. This study was conducted to report the national rates and the timing of proximal and distal reoperations after operative repair of TAAD based on available patient-level admissions data.
Methods: Admissions data for patients with TAAD were identified and obtained from Thomson Reuters MarketScan Database using International Classification of Diseases, 9th Revision, Clinical Modification codes. From 2003 to 2011, patients aged >18 years with thoracic or thoracoabdominal diagnoses who underwent surgical repair or aortic resection, or both, were identified. From this population, 2041 patients with $12 months of follow-up data who were discharged alive after index admissions for TAAD were described. Primary outcome measures were rates of reoperation for any aortic location. Patient demographics, comorbidities at admission, and interval to reoperation were also obtained from the database.
Results: A total of 3463 patients with TAAD who underwent repair were identified. The mortality rate was 7.8% for the initial repair. Of 3018 patients who were available for follow-up, 2041 patients had >1 year of follow-up. The mean age was 58.0 6 13.2 years, and 70% were male. Eighty-seven patients (4.26%) required 95 reoperations (33.1% of reoperations) for the ascending aorta, and 162 (7.94%) patients required 192 (66.9%) reoperations for the descending thoracic aorta. The mean intervals were 436.7 6 593.9 days for ascending aortic surgery and 324.0 6 431.2 days for the descending thoracic aorta after the initial admission for TAAD surgical procedures.
Conclusions: TAAD is a highly morbid and mortal diagnosis. The initial surgery is high-risk, but our data demonstrate that future surgery is common. In fact, the majority of the repeat surgical procedures are for descending thoracic aortic complications. We believe that more aggressive aortic stabilization may be warranted. Methods: The Inpatient Medicare database from 2004 to 2011 was investigated using International Classification of Diseases, 9th Revision procedure codes for repair of abdominal, thoracic, and thoracoabdominal aortic aneurysms with associated concomitant renal or mesenteric revascularization for OR and ER. Fenestrated endovascular grafting codes were used once available in 2011. Demographics, preoperative comorbidities, mortalities, and postoperative complications were analyzed using the t-test for continuous and the c 2 test for categoric variables. Kaplan-Meier curves and multivariable Cox models were used to estimate effect of treatment on survival.
Results: A total of 4749 patients met inclusion criterion: 3757 OR and 992 ER groups. The 30-day mortality was significantly less after ER (mean mortality: 12.3 for OR vs 8.2 for ER; P < .001). Patients after OR had higher rates of renal failure (15.3% vs 9.4%) and cardiac (4.5% vs 2.3%) and pulmonary insufficiency (11.5% vs3.6%). ER patients had higher rates of peripheral vascular (1.8% vs 1%) and device malfunction (6.9% vs 1.1%) complications. Although survival up to almost 2 years was better after ER, survival curves converged after 21 months of follow-up (Fig 1) . Propensity-matched patients confirmed a 2-year advantage for ER over OR (Fig 2) .
Conclusions: Like ER of abdominal aortic aneurysm, ER of thoracoabdominal and juxtarenal aneurysms has a distinct 2-year advantage but then becomes not statistically different at up to 7 years of followup. This may reflect the prevalence of other comorbidities resulting in late mortality in both groups. This preliminary study based on national results does support more in-depth long-term prospective analysis, especially as techniques for thoracoabdominal repair become more standardized and widespread. Results: A total of 1362 patients undergoing LE intervention with IVUS were matched to 2724 patients not receiving IVUS. Mean age was 75 years, 52.6% were men, and 79.1% were white. The most common indications were claudication (29.6%) and ulceration/gangrene (25.9%). No differences in complications for IVUS vs non-IVUS, respectively, were identified: cardiac (2.3% vs 2.4%; P ¼ .9), renal (6.8% vs 7.9%; P ¼ .2), bleeding (8.3% vs 8.2%; P ¼ .9), and embolism or thrombosis (6.4% vs 7.9%; P ¼ .08). Total charges ($73,516 vs $69,221; P ¼ .046) and supply costs ($23,644 vs $15,322; P < .0001) were significantly higher with IVUS. The 30-day above-knee (1.8% vs 1.4%; P ¼ .4) and below-knee (3.2% vs 3.1%; P ¼ .9) amputation rates did not differ between IVUS and non-IVUS, respectively (Fig 1) . The 30-day rates of repeat angioplasty (9.6% vs 8.7; P ¼ .3) and embolectomy (1.3% vs 1.6%; P ¼ .4) did not differ, whereas rates of stenting (7.5% vs 5.5%; P ¼ .01) and thrombolysis (3.4% vs 1.3%; P < .0001) were higher for IVUS. Modeling demonstrated that IVUS use was not associated with reduced amputation rates (hazard ratio [HR], 1.03; 95% confidence interval [CI] , 0.76-1.4), whereas black race (HR, 1.58; 95% CI, 1.12-2.23), renal failure (HR, 1.82; 95% CI, 1.30-2.56), and disease severity were associated with amputation.
Conclusions: As an adjunctive tool during infrainguinal interventions, IVUS was not associated with improved 30-day major amputation but was more frequently associated with thrombolysis and stenting. Total charges and supply costs were significantly greater with IVUS, suggesting that IVUS does not improve outcomes while increasing hospital utilization.
